Entity

Time filter

Source Type

Romanshorn, Switzerland

Patent
Max Zeller Soehne Ag | Date: 2013-07-03

The present invention relates to the novel use of an extract from a


Schellenberg R.,Institute for Health Care and Science | Zimmermann C.,Max Zeller Soehne AG | Drewe J.,Max Zeller Soehne AG | Hoexter G.,Dr. M. Koehler GmbH Pharma Biometrie Consulting | Zahner C.,Max Zeller Soehne AG
Phytomedicine | Year: 2012

Background: Preparations of Vitex agnus castus L. (VAC) have been shown to be effective to treat irregular menstrual cycles, cyclical mastalgia and symptoms of the premenstrual syndrome (PMS). However, the dose-effect relationship for the treatment of PMS has not yet been established. This study aimed to investigate the clinical effects of three different doses of the VAC extract Ze 440 in comparison to placebo in patients suffering from PMS. Methods: In a multicenter, double-blind, placebo-controlled, parallel-group study, 162 female patients with PMS (18-45 years) were randomized to either placebo or different doses of Ze 440 (8, 20 and 30 mg) over three menstrual cycles. PMS symptoms' severity was assessed by patients using visual analog scales (VAS) for the symptoms irritability, mood alteration, anger, headache, bloating and breast fullness. Results: Each of the treatments was well tolerated. Improvement in the total symptom score (TSS) in the 20 mg group was significantly higher than in the placebo and 8 mg treatment group. The higher dose of 30 mg, on the other hand, did not significantly decrease symptom severity compared to the 20 mg treatment, providing a rational for the usage of 20 mg. Corresponding results were observed with the single PMS symptom scores. Conclusion: This study demonstrated that the VAC extract Ze 440 was effective in relieving symptoms of PMS, when applied in a dose of 20 mg. Therefore, for patients suffering from PMS, 20 mg Ze 440 should be the preferred daily dose. © 2012 Elsevier GmbH. Source


Moser C.,Max Zeller Soehne AG | Vickers S.P.,RenaSci Ltd. | Brammer R.,RenaSci Ltd. | Cheetham S.C.,RenaSci Ltd. | Drewe J.,Max Zeller Soehne AG
Phytomedicine | Year: 2014

Introduction It was the aim of the present experiments to examine potential antidiabetic effects of the Cimicifuga racemosa extract Ze 450. Methods Ze 450 and some of its components (23-epi-26-deoxyactein, protopine and cimiracemoside C) were investigated in vitro for their effects on AMP-activated protein kinase (AMPK) compared to metformin in HepaRG cells. Ze 450 (given orally (PO) and intraperitonally (IP)), metformin (PO) and controls were given over 7 days to 68 male ob/ob mice. Glucose and insulin concentrations were measured at baseline and during an oral glucose tolerance test (OGTT). Results Ze 450 and its components activated AMPK to the same extent as metformin. In mice, Ze 450 (PO/IP) decreased significantly average daily and cumulative weight gain, average daily food and water intake, while metformin had no effect. In contrast to metformin, PO Ze 450 virtually did not change maximum glucose levels during OGTT, however, prolonged elimination. Ze 450 administered PO and IP decreased significantly post-stimulated insulin, whereas metformin did not. HOMA-IR index of insulin resistance improved significantly after IP and PO Ze 450 and slightly after metformin. In summary, the results demonstrate that Ze 450 reduced significantly body weight, plasma glucose, improved glucose metabolism and insulin sensitivity in diabetic ob/ob mice. In vitro experiments suggest that part of the effects may be related to AMPK activation. Conclusions Ze 450 may have utility in the treatment of type 2 diabetes. However, longer term studies in additional animal models or patients with disturbed glucose tolerance or diabetes may be of use to investigate this further. © 2014 Elsevier GmbH. All rights reserved. Source

Discover hidden collaborations